MBX Biosciences Statistics
Total Valuation
MBX Biosciences has a market cap or net worth of $3.03 billion. The enterprise value is $2.62 billion.
| Market Cap | 3.03B |
| Enterprise Value | 2.62B |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MBX Biosciences has 48.16 million shares outstanding. The number of shares has increased by 62.14% in one year.
| Current Share Class | 48.16M |
| Shares Outstanding | 48.16M |
| Shares Change (YoY) | +62.14% |
| Shares Change (QoQ) | +2.41% |
| Owned by Insiders (%) | 2.74% |
| Owned by Institutions (%) | 82.51% |
| Float | 30.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.38 |
| P/TBV Ratio | 7.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.08, with a Debt / Equity ratio of 0.01.
| Current Ratio | 18.08 |
| Quick Ratio | 17.82 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -33.17% and return on invested capital (ROIC) is -23.29%.
| Return on Equity (ROE) | -33.17% |
| Return on Assets (ROA) | -22.08% |
| Return on Invested Capital (ROIC) | -23.29% |
| Return on Capital Employed (ROCE) | -28.60% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.66M |
| Employee Count | 63 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +340.25% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +340.25% |
| 50-Day Moving Average | 61.51 |
| 200-Day Moving Average | 39.80 |
| Relative Strength Index (RSI) | 45.98 |
| Average Volume (20 Days) | 427,348 |
Short Selling Information
The latest short interest is 4.95 million, so 10.28% of the outstanding shares have been sold short.
| Short Interest | 4.95M |
| Short Previous Month | 5.19M |
| Short % of Shares Out | 10.28% |
| Short % of Float | 15.97% |
| Short Ratio (days to cover) | 8.26 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -117.92M |
| Pretax Income | -104.29M |
| Net Income | -104.29M |
| EBITDA | -117.66M |
| EBIT | -117.92M |
| Earnings Per Share (EPS) | -$2.41 |
Balance Sheet
The company has $418.58 million in cash and $3.34 million in debt, with a net cash position of $415.24 million or $8.62 per share.
| Cash & Cash Equivalents | 418.58M |
| Total Debt | 3.34M |
| Net Cash | 415.24M |
| Net Cash Per Share | $8.62 |
| Equity (Book Value) | 409.54M |
| Book Value Per Share | 8.54 |
| Working Capital | 404.20M |
Cash Flow
In the last 12 months, operating cash flow was -$82.67 million and capital expenditures -$2.53 million, giving a free cash flow of -$85.20 million.
| Operating Cash Flow | -82.67M |
| Capital Expenditures | -2.53M |
| Depreciation & Amortization | 253,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -85.20M |
| FCF Per Share | -$1.77 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MBX Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -62.14% |
| Shareholder Yield | -62.14% |
| Earnings Yield | -3.44% |
| FCF Yield | -2.81% |
Analyst Forecast
The average price target for MBX Biosciences is $88.36, which is 40.25% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $88.36 |
| Price Target Difference | 40.25% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |